Cobimetinib is approved for treatment of?
Cobimetinib is approved for RX of melanoma in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in conjunction with Vemurafenib. Cobimetinib - Reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase.
BCC
Melanoma
Squamous cell carcinoma
Vitiligo
Tumours of skin